Dyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month Low - What's Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Saturday . The stock traded as low as $14.79 and last traded at $15.87, with a volume of 9825974 shares changing hands. The stock had previously closed at $23.05.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DYN. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Friday. Raymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an "outperform" rating and a $46.00 target price for the company. Chardan Capital reissued a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday. Finally, StockNews.com lowered Dyne Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $49.91.

Dyne Therapeutics Stock Performance

The company has a 50-day moving average of $27.04 and a 200-day moving average of $34.02. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -4.46 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 782 shares of the firm's stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now directly owns 15,962 shares of the company's stock, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dirk Kersten sold 23,671 shares of the business's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total value of $836,769.85. Following the completion of the transaction, the director now owns 99,652 shares in the company, valued at $3,522,698.20. The trade was a 19.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,742 shares of company stock valued at $1,443,246. 20.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company's stock valued at $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC grew its position in Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock worth $244,755,000 after acquiring an additional 2,189,339 shares in the last quarter. State Street Corp increased its stake in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company's stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. RTW Investments LP raised its position in Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock valued at $244,926,000 after purchasing an additional 431,503 shares in the last quarter. Finally, RA Capital Management L.P. raised its position in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.